Efficacy of corticosteroids in acute respiratory distress syndrome

An observational study

A. Prabhu Varsha, Awasthi Shivanshu, Shanavas Rithu, Kunhikatta Vijayanarayana, Thunga Girish, Nair Sreedharan, Acharya Raviraja

Research output: Contribution to journalArticle

Abstract

Background: Deficits in the treatment options makes Acute Respiratory Distress Syndrome (ARDS) management more challenging. With Involvement of inflammatory pathways, corticosteroid remains a vital choice for ARDS treatment. However lack of studies and presence of ambiguity in results with use of glucocorticoids makes it imperative to carry out more research. The aim of the study was to assess the efficacy of glucocorticoids in the treatment of ARDS and to identify the treatment pattern of ARDS. Methods: Retrospective observational study, involving 150 patients with confirmed diagnosis of ARDS admitted during January 2011 to December 2011 in a tertiary care hospital. Demographics, social habits, and association between glucocorticoid initiation and respective onset and outcomes like mortality and free ventilator days, were analysed by Chi square test and p<0.05 was considered to be statistically significant. Data analysis was done by using SPSS version 16. Results: Mean age of our study population was 43.37 ± 16.15 with male 60.7% and 39.3% female. The study found reduced mortality (41.7%) in the glucocorticoid treatment group compared to the non-glucocorticoid group (56.4%) (p < 0.022). Among the glucocorticoid treated subgroups, in the early start subgroup there was a statistically significant reduction of mean ventilator days (4.61 ± 2.81 vs 6.44 ± 4.47) and mortality (30.9% vs 80%, p <0.001). Conclusions: The use of glucocorticoids in ARDS showed benefits, especially when started early in the course of treatment with reduced mortality and decreased ventilator days. However small sample size precluded the power of detection of important outcome such as mortality and more research is necessary to establish the role of glucocorticoid therapy in ARDS.

Original languageEnglish
Pages (from-to)65-68
Number of pages4
JournalJournal of Young Pharmacists
Volume9
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Adult Respiratory Distress Syndrome
Glucocorticoids
Observational Studies
Adrenal Cortex Hormones
Mechanical Ventilators
Mortality
Therapeutics
Tertiary Healthcare
Chi-Square Distribution
Research
Tertiary Care Centers
Sample Size
Habits
Retrospective Studies
Demography
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{5a47c128c00840d58440c163a8634878,
title = "Efficacy of corticosteroids in acute respiratory distress syndrome: An observational study",
abstract = "Background: Deficits in the treatment options makes Acute Respiratory Distress Syndrome (ARDS) management more challenging. With Involvement of inflammatory pathways, corticosteroid remains a vital choice for ARDS treatment. However lack of studies and presence of ambiguity in results with use of glucocorticoids makes it imperative to carry out more research. The aim of the study was to assess the efficacy of glucocorticoids in the treatment of ARDS and to identify the treatment pattern of ARDS. Methods: Retrospective observational study, involving 150 patients with confirmed diagnosis of ARDS admitted during January 2011 to December 2011 in a tertiary care hospital. Demographics, social habits, and association between glucocorticoid initiation and respective onset and outcomes like mortality and free ventilator days, were analysed by Chi square test and p<0.05 was considered to be statistically significant. Data analysis was done by using SPSS version 16. Results: Mean age of our study population was 43.37 ± 16.15 with male 60.7{\%} and 39.3{\%} female. The study found reduced mortality (41.7{\%}) in the glucocorticoid treatment group compared to the non-glucocorticoid group (56.4{\%}) (p < 0.022). Among the glucocorticoid treated subgroups, in the early start subgroup there was a statistically significant reduction of mean ventilator days (4.61 ± 2.81 vs 6.44 ± 4.47) and mortality (30.9{\%} vs 80{\%}, p <0.001). Conclusions: The use of glucocorticoids in ARDS showed benefits, especially when started early in the course of treatment with reduced mortality and decreased ventilator days. However small sample size precluded the power of detection of important outcome such as mortality and more research is necessary to establish the role of glucocorticoid therapy in ARDS.",
author = "Varsha, {A. Prabhu} and Awasthi Shivanshu and Shanavas Rithu and Kunhikatta Vijayanarayana and Thunga Girish and Nair Sreedharan and Acharya Raviraja",
year = "2017",
doi = "10.5530/jyp.2017.9.13",
language = "English",
volume = "9",
pages = "65--68",
journal = "Journal of Young Pharmacists",
issn = "0975-1483",
publisher = "E-Flow Medknow Publications",
number = "1",

}

Efficacy of corticosteroids in acute respiratory distress syndrome : An observational study. / Varsha, A. Prabhu; Shivanshu, Awasthi; Rithu, Shanavas; Vijayanarayana, Kunhikatta; Girish, Thunga; Sreedharan, Nair; Raviraja, Acharya.

In: Journal of Young Pharmacists, Vol. 9, No. 1, 2017, p. 65-68.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of corticosteroids in acute respiratory distress syndrome

T2 - An observational study

AU - Varsha, A. Prabhu

AU - Shivanshu, Awasthi

AU - Rithu, Shanavas

AU - Vijayanarayana, Kunhikatta

AU - Girish, Thunga

AU - Sreedharan, Nair

AU - Raviraja, Acharya

PY - 2017

Y1 - 2017

N2 - Background: Deficits in the treatment options makes Acute Respiratory Distress Syndrome (ARDS) management more challenging. With Involvement of inflammatory pathways, corticosteroid remains a vital choice for ARDS treatment. However lack of studies and presence of ambiguity in results with use of glucocorticoids makes it imperative to carry out more research. The aim of the study was to assess the efficacy of glucocorticoids in the treatment of ARDS and to identify the treatment pattern of ARDS. Methods: Retrospective observational study, involving 150 patients with confirmed diagnosis of ARDS admitted during January 2011 to December 2011 in a tertiary care hospital. Demographics, social habits, and association between glucocorticoid initiation and respective onset and outcomes like mortality and free ventilator days, were analysed by Chi square test and p<0.05 was considered to be statistically significant. Data analysis was done by using SPSS version 16. Results: Mean age of our study population was 43.37 ± 16.15 with male 60.7% and 39.3% female. The study found reduced mortality (41.7%) in the glucocorticoid treatment group compared to the non-glucocorticoid group (56.4%) (p < 0.022). Among the glucocorticoid treated subgroups, in the early start subgroup there was a statistically significant reduction of mean ventilator days (4.61 ± 2.81 vs 6.44 ± 4.47) and mortality (30.9% vs 80%, p <0.001). Conclusions: The use of glucocorticoids in ARDS showed benefits, especially when started early in the course of treatment with reduced mortality and decreased ventilator days. However small sample size precluded the power of detection of important outcome such as mortality and more research is necessary to establish the role of glucocorticoid therapy in ARDS.

AB - Background: Deficits in the treatment options makes Acute Respiratory Distress Syndrome (ARDS) management more challenging. With Involvement of inflammatory pathways, corticosteroid remains a vital choice for ARDS treatment. However lack of studies and presence of ambiguity in results with use of glucocorticoids makes it imperative to carry out more research. The aim of the study was to assess the efficacy of glucocorticoids in the treatment of ARDS and to identify the treatment pattern of ARDS. Methods: Retrospective observational study, involving 150 patients with confirmed diagnosis of ARDS admitted during January 2011 to December 2011 in a tertiary care hospital. Demographics, social habits, and association between glucocorticoid initiation and respective onset and outcomes like mortality and free ventilator days, were analysed by Chi square test and p<0.05 was considered to be statistically significant. Data analysis was done by using SPSS version 16. Results: Mean age of our study population was 43.37 ± 16.15 with male 60.7% and 39.3% female. The study found reduced mortality (41.7%) in the glucocorticoid treatment group compared to the non-glucocorticoid group (56.4%) (p < 0.022). Among the glucocorticoid treated subgroups, in the early start subgroup there was a statistically significant reduction of mean ventilator days (4.61 ± 2.81 vs 6.44 ± 4.47) and mortality (30.9% vs 80%, p <0.001). Conclusions: The use of glucocorticoids in ARDS showed benefits, especially when started early in the course of treatment with reduced mortality and decreased ventilator days. However small sample size precluded the power of detection of important outcome such as mortality and more research is necessary to establish the role of glucocorticoid therapy in ARDS.

UR - http://www.scopus.com/inward/record.url?scp=85010698132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010698132&partnerID=8YFLogxK

U2 - 10.5530/jyp.2017.9.13

DO - 10.5530/jyp.2017.9.13

M3 - Article

VL - 9

SP - 65

EP - 68

JO - Journal of Young Pharmacists

JF - Journal of Young Pharmacists

SN - 0975-1483

IS - 1

ER -